Phase III Placebo-Controlled, Randomized Clinical Trial With Synthetic Crohn's Disease Patients to Evaluate Treatment Response
V. Abedi*,a; P. Lu*,a; R. Hontecillas*; M. Verma*; G.A. Vess*; C.W. Philipson†; A. Carbo†; A. Leber*; N.T. Juni*; S. Hoops*; J. Bassaganya-Riera* * Nutritional Immunology and Molecular Medicine Laboratory, Virginia Bioinformatics Institute, Virginia Tech, Blacksburg, VA, United States† BioTherapeutics Inc., Blacksburg, VA, United Statesa These authors contributed equally to this work.
Abstract
Crohn's disease (CD) is one of the two most prevailing clinical manifestations of inflammatory bowel disease (IBD), a disease that afflicts 1.4 million Americans and 4 million people worldwide. The current treatment ...
Get Emerging Trends in Applications and Infrastructures for Computational Biology, Bioinformatics, and Systems Biology now with the O’Reilly learning platform.
O’Reilly members experience books, live events, courses curated by job role, and more from O’Reilly and nearly 200 top publishers.
